COLLEGE STATION, TX / ACCESSWIRE / July 21, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).
Biogenysis, Inc. (“BGEN”), a wholly owned subsidiary of Enzolytics, Inc. (the “Firm” or “ENZC”), a drug pattern biotech company, announced this day a partnership with Khalpey AI Lab to title biomarkers for early onset Alzheimer’s illness.
Alzheimer’s illness impacts over 5.2 million Americans over the age of 65 and hundreds and hundreds below 65 with early-onset Alzheimer’s. Discovering and validating illness biomarkersare serious in diagnosing, treating, and predicting the illness. Excessive-throughput technology generates tall biological records, nonetheless AI can organize and account for complex datasets in microbiome compare, genetics, and vitamin, providing promising avenues for determining and combating Alzheimer’s illness.
The collaboration aims to title biomarkers for early-onset Alzheimer’s illness and fresh therapeutic targets to lengthen the progression of the illness.
Dr. Zain Khalpey, Director of the AI Lab (https://khalpey-ai.com ), acknowledged, “The long term in AI is no longer a present, nonetheless an achievement. Our lab strives to electrify this in utilized AI objects in healthcare at the bedside with our partners. Our AI Lab brings clinically utilized synthetic intelligence to the affected person bedside and specializes in a better future. While standing at the forefront of scientific technology, our compare helps to electrify a more shimmering the following day by elevating affected person records sequence and evaluation to a brand original diploma. With one gaze on the future, our innovative tools are serving to healthcare professionals plot better-advised scientific choices and even predict and prevent adversarial affected person occasions earlier than they occur. This integration with the Biogenysis AI platform enormously improves our AI tools and scientific outcomes.”
Dr. Gaurav Chandra, CEO of Biogenysis, Inc., acknowledged, “This partnership showcases our Firm’s dedication to advancing the field of drug discovery by synthetic intelligence. We employ AI to increase drug discovery and expand our IP portfolio. Our AI platform advances healthcare from reactive to predictive, preventive, personalized, and participatory care.” Dr. Chandra added, “We purpose to title early biomarkers for Alzheimer’s illness and affirm original therapeutic targets to gradual its progression. The AI mannequin comprises genetics, vitamin, and microbiome and is also utilized to other power diseases. We welcome this partnership with Dr. Zain Khalpey’s AI Lab as this might perchance enormously flee up our progress in the field of providing efficient health center treatment.”
Enzolytics, Inc. Overview
Enzolytics, Inc. is a drug pattern company dedicated to commercializing its more than one proprietary proteins and monoclonal antibodies focusing on heaps of infectious diseases. The Firm has proprietary technology for producing fully human monoclonal antibodies (mAbs) in opposition to more than one infectious diseases. This technology is in the meanwhile being employed to secure monoclonal antibody therapeutics for treating the CoronaVirus (SARS-CoV-2), HIV-1, and the Pussycat Leukemia virus. The Firm has also acknowledged conserved epitopes on and has plans to secure mAbs focusing on many other viruses, along side HIV-2, Influenza A and B, H1N1 influenza, Respiratory syncytial virus (RSV), Minute-Pox, Ebola Virus, Tetanus, Diphtheria, HTLV-1/2, Rabies, Herpes zoster, Varicella zoster, Anthrax, Mason-Pfizer monkey virus (MPMV) and Visna virus (VISNA). The Firm has also analyzed epitopes of animal viruses and plans to secure mAbs for treating these animal viruses.
The Firm is also advancing a patented and clinically examined therapeutic compound, ITV-1 (Immune Therapeutic Vaccine-1). ITV-1 is a suspension of Inactivated Pepsin Fraction (IPF), covered by U.S. Patent Nos. 8,066,982 and 7,479,538. Learn secure shown it to be efficient in treating HIV/AIDS. ITV-1 has also been shown to modulate the immune machine.
Safe Harbor Assertion: This records begin contains forward-making an strive statements that hold dangers and uncertainties associated with financial projections, budgets, milestone timelines, scientific pattern, regulatory approvals, and other dangers described by Enzolytics, Inc. every so many times in its periodic reports filed with the SEC. ITV-1 is no longer well-liked by the U.S. Food and Drug Administration or by any comparable regulatory agencies in other locations on the earth.
While Enzolytics, Inc. believes that the forward-making an strive statements and underlying assumptions contained therein are realistic, any of the assumptions will be unsuitable, along side, nonetheless no longer restricted to, the ability of Enzolytics to keep the efficacy of its therapeutics in the medication of any illness or properly being condition, the reach of compare and ideas leading to commercialization of its therapeutics in the United States, the obtaining of funding required to enact the reach notion, the completion of compare and tests on time or at all, and the worthwhile of such compare or tests. Therefore, there might perchance be also no assurance that the forward-making an strive statements incorporated on this begin will demonstrate to be correct model.
Such forward-making an strive statements are based totally mostly on present expectations. They hold inherent dangers and uncertainties, along side components that will moreover lengthen, divert or swap any of the statements made, and trigger real outcomes and outcomes to change materially from present expectations. No forward-making an strive assertion is also assured. These forward-making an strive statements are made as of the date of this press begin. The Firm expressly disclaims any intention or responsibility to interchange the forward-making an strive statements or change the the explanation why real outcomes might perchance well moreover vary from those projected in the forward-making an strive statements.
1101 Raintree Circle
Allen, Texas 75013
SOURCE: Enzolytics, Inc.